ADAMTS13, recombinant-krhn (Adzynma; formerly TAK-755, BAX930, SHP655) (Takeda Pharmaceutical Co. Ltd.) is an intravenous human recombinant A disintegrin and metalloproteinase with thrombospondin motifs 13 (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.